{"id":51827,"date":"2025-12-23T14:03:45","date_gmt":"2025-12-23T06:03:45","guid":{"rendered":"https:\/\/flcube.com\/?p=51827"},"modified":"2025-12-23T14:03:46","modified_gmt":"2025-12-23T06:03:46","slug":"jemincare-jmx-2005-pad-injection-secures-nmpa-clinical-trial-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51827","title":{"rendered":"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval"},"content":{"rendered":"\n<p><strong>Jiangxi Jemincare Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603222:SHA\">SHA: 603222<\/a>) announced that its <strong>Class\u202f2.2 and Class\u202f2.4 new drug application<\/strong> for <strong>JMX-2005 Injection<\/strong> has been approved by the <strong>National Medical Products Administration (NMPA)<\/strong> for clinical trials. The drug is intended to improve ischemic symptoms\u2014such as resting pain and ulcers\u2014caused by <strong>Peripheral Artery Disease (PAD)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangxi Jemincare Group (603222.SH)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>JMX-2005 Injection<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA clinical trial approval (Class\u202f2.2, Class\u202f2.4)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Ischemic symptoms from PAD (resting pain, ulcers)<\/td><\/tr><tr><td>**Mechanism<\/td><td>Sustained\u2011release liposome formulation with subcutaneous &#8220;drug reservoir&#8221;<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-burden-amp-unmet-medical-need\">Disease Burden &amp; Unmet Medical Need<\/h2>\n\n\n\n<p><strong>Peripheral Artery Disease (PAD):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Affects <strong>45 million<\/strong> patients in China; severe stages impact <strong>5\u201110%<\/strong> of cases<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong>: Chronic resting pain, non\u2011healing ulcers, <strong>amputation risk<\/strong> in advanced disease<\/li>\n\n\n\n<li><strong>Quality of Life<\/strong>: Severely impairs patient mobility and daily functioning<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Limited pharmacologic options; surgical revascularization for severe cases only<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-innovation-sustained-release-liposome-platform\">Technology Innovation: Sustained-Release Liposome Platform<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Innovation<\/th><th>Clinical Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Formulation<\/strong><\/td><td>Advanced liposome encapsulation<\/td><td>Controlled\u2011release characteristics<\/td><\/tr><tr><td><strong>Delivery<\/strong><\/td><td>Subcutaneous injection<\/td><td>Creates localized &#8220;drug reservoir&#8221; at injection site<\/td><\/tr><tr><td><strong>Release Profile<\/strong><\/td><td>Slow, continuous drug release<\/td><td>Extends dosing interval<\/td><\/tr><tr><td><strong>Patient Impact<\/strong><\/td><td>Reduced injection frequency<\/td><td><strong>Improved compliance<\/strong> for chronic PAD management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Market Insight<\/th><\/tr><\/thead><tbody><tr><td><strong>PAD Drug Market<\/strong><\/td><td>China market valued at <strong>\u00a58 billion<\/strong> (US$1.1 billion), growing at 6% CAGR<\/td><\/tr><tr><td><strong>Sustained\u2011Release Gap<\/strong><\/td><td>No approved sustained\u2011release injectables for PAD ischemic symptoms<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>First liposome\u2011based PAD therapy in China; offers disease\u2011modifying potential<\/td><\/tr><tr><td><strong>Pipeline Position<\/strong><\/td><td>Jemincare&#8217;s lead asset in vascular disease franchise<\/td><\/tr><tr><td><strong>Regulatory Path<\/strong><\/td><td>Class\u202f2.2\/2.4 designation accelerates review; potential priority review if Phase\u202f2 data positive<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-next-steps\">Strategic Outlook &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development<\/strong>: Phase\u202f1 trial initiation expected <strong>Q1\u202f2026<\/strong>; safety and PK evaluation in healthy volunteers<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: In\u2011house liposome production facility will scale to support pivotal trials<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Platform technology applicable to other ischemic diseases (diabetic foot ulcers, critical limb ischemia)<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Analysts project <strong>\u00a5500\u2011800 million<\/strong> (US$70\u2011110 million) peak China sales if approved<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: NMPA approval may support IND filings in <strong>US\/EU<\/strong> via manufacturing comparability data<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding JMX\u20112005 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangxi Jemincare Group (SHA: 603222) announced that its Class\u202f2.2 and Class\u202f2.4 new drug application for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51833,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1699,1768],"class_list":["post-51827","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-jemincare","tag-sha-603222"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangxi Jemincare Group (SHA: 603222) announced that its Class\u202f2.2 and Class\u202f2.4 new drug application for JMX-2005 Injection has been approved by the National Medical Products Administration (NMPA) for clinical trials. The drug is intended to improve ischemic symptoms\u2014such as resting pain and ulcers\u2014caused by Peripheral Artery Disease (PAD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51827\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval\" \/>\n<meta property=\"og:description\" content=\"Jiangxi Jemincare Group (SHA: 603222) announced that its Class\u202f2.2 and Class\u202f2.4 new drug application for JMX-2005 Injection has been approved by the National Medical Products Administration (NMPA) for clinical trials. The drug is intended to improve ischemic symptoms\u2014such as resting pain and ulcers\u2014caused by Peripheral Artery Disease (PAD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51827\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-23T06:03:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-23T06:03:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval\",\"datePublished\":\"2025-12-23T06:03:45+00:00\",\"dateModified\":\"2025-12-23T06:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827\"},\"wordCount\":373,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2306.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Jemincare\",\"SHA: 603222\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51827#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51827\",\"name\":\"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2306.webp\",\"datePublished\":\"2025-12-23T06:03:45+00:00\",\"dateModified\":\"2025-12-23T06:03:46+00:00\",\"description\":\"Jiangxi Jemincare Group (SHA: 603222) announced that its Class\u202f2.2 and Class\u202f2.4 new drug application for JMX-2005 Injection has been approved by the National Medical Products Administration (NMPA) for clinical trials. The drug is intended to improve ischemic symptoms\u2014such as resting pain and ulcers\u2014caused by Peripheral Artery Disease (PAD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51827\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2306.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51827#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangxi Jemincare Group (SHA: 603222) announced that its Class\u202f2.2 and Class\u202f2.4 new drug application for JMX-2005 Injection has been approved by the National Medical Products Administration (NMPA) for clinical trials. The drug is intended to improve ischemic symptoms\u2014such as resting pain and ulcers\u2014caused by Peripheral Artery Disease (PAD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51827","og_locale":"en_US","og_type":"article","og_title":"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval","og_description":"Jiangxi Jemincare Group (SHA: 603222) announced that its Class\u202f2.2 and Class\u202f2.4 new drug application for JMX-2005 Injection has been approved by the National Medical Products Administration (NMPA) for clinical trials. The drug is intended to improve ischemic symptoms\u2014such as resting pain and ulcers\u2014caused by Peripheral Artery Disease (PAD).","og_url":"https:\/\/flcube.com\/?p=51827","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-23T06:03:45+00:00","article_modified_time":"2025-12-23T06:03:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51827#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51827"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval","datePublished":"2025-12-23T06:03:45+00:00","dateModified":"2025-12-23T06:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51827"},"wordCount":373,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51827#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2306.webp","keywords":["Clinical trial approval \/ initiation","Jemincare","SHA: 603222"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51827#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51827","url":"https:\/\/flcube.com\/?p=51827","name":"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51827#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51827#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2306.webp","datePublished":"2025-12-23T06:03:45+00:00","dateModified":"2025-12-23T06:03:46+00:00","description":"Jiangxi Jemincare Group (SHA: 603222) announced that its Class\u202f2.2 and Class\u202f2.4 new drug application for JMX-2005 Injection has been approved by the National Medical Products Administration (NMPA) for clinical trials. The drug is intended to improve ischemic symptoms\u2014such as resting pain and ulcers\u2014caused by Peripheral Artery Disease (PAD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51827#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51827"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51827#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2306.webp","width":1080,"height":608,"caption":"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51827#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51827"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51827\/revisions"}],"predecessor-version":[{"id":51834,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51827\/revisions\/51834"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51833"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}